Trial Profile
A Phase II, Randomized, Vehicle-Controlled, Double-Blind, Multi-Center Study to Evaluate Safety and Efficacy of MBI 226 1.25% and 2.5% Acne Solutions Applied Topically for 12 Weeks to Subjects With Acne Vulgaris.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2010
Price :
$35
*
At a glance
- Drugs Omiganan (Primary)
- Indications Acne vulgaris
- Focus Therapeutic Use
- Sponsors Carrus Capital Corporation
- 08 Apr 2010 New trial record